Skip to main content
. 2018 May 9;14(5):1161–1174. doi: 10.1080/21645515.2018.1457595

Table 4.

Number (percentage) of participants with solicited, unsolicited and serious adverse events after each MenABCWY+OMV dose.

  Group III Group VI   Group VII  
  Booster dose 1st dose 2nd dose 1st dose 2nd dose
  N=33 N=46 N=46 N=50 N=50
Local symptoms          
 Any 31 (94%) 41 (89%) 35 (78%) 47 (94%) 41 (82%)
Pain          
 Any 31 (94%) 41 (89%) 34 (76%) 47 (94%) 41 (82%)
 Severe 6 (18%) 8 (17%) 2 (4%) 6 (12%) 3 (6%)
Erythema          
 Any 8 (24%) 7 (16%) 6 (13%) 8 (16%) 7 (14%)
 Severe 1 (3%) 1 (2%) 0 0 0
Induration          
 Any 12 (36%) 7 (15%) 9 (20%) 13 (26%) 8(16%)
 Severe 0 0 0 1 (2%) 0
General symptoms          
 Any 24 (73%) 35 (76%) 22 (49%) 37 (74%) 28 (56%)
Chills          
 Any 5 (15%) 11 (24%) 5 (11%) 11 (22%) 9 (18%)
 Severe 1 (3%) 0 1 (2%) 0 1 (2%)
Loss of appetite          
 Any 5 (15%) 9 (20%) 3 (7%) 9 (18%) 5 (10%)
 Severe 0 0 0 1 (2%) 2 (4%)
Headache          
 Any 19 (58%) 20 (43%) 11 (25%) 23 (46%) 18 (36%)
 Severe 0 1 (2%) 2 (5%) 3 (6%) 4 (8%)
Fatigue          
 Any 14 (42%) 19 (42%) 10 (23%) 24 (48%) 12 (24%)
 Severe 0 1 (2%) 1 (2%) 0 1 (2%)
Myalgia          
 Any 18 (55%) 22 (48%) 12 (27%) 23 (46%) 14 (28%)
 Severe 0 0 1 (2%) 1 (2%) 2 (4%)
Arthralgia          
 Any 8 (24%) 8 (17%) 4 (9%) 15 (30%) 7 (14%)
 Severe 0 0 1 (2%) 0 1 (2%)
Nausea          
 Any 4 (12%) 10 (22%) 4 (9%) 13 (26%) 4 (8%)
 Severe 0 1 (2%) 0 0 0
Fever          
 Any(≥38°C) 0 4 (9%) 4 (9%) 8 (16%) 2 (4%)
 Severe(≥40°C) 0 0 0 0 0
Unsolicited symptoms 11 (33%) 21 (46%)   20 (40%)  
Possibly related unsolicited AEs 3 (9%) 11 (24%)   8 (16%)  
Medically-attended AEs 2 (6%) 6 (13%)   5 (10%)  
SAEs 0 0 0    

Footnote: N, maximum number of participants with available results; AE, adverse event; SAE, serious adverse event.